We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

74 hedge funds and large institutions have $68.9M invested in Syndax Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 22 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

607% more call options, than puts

Call options by funds: $2.05M | Put options by funds: $290K

14% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 22

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

1% less funds holding

Funds holding: 75 → 74 (-1)

3.38% less ownership

Funds ownership: 65.66% → 62.28% (-3.4%)

44% less capital invested

Capital invested by funds: $124M → $68.9M (-$55.1M)

Holders
74
Holders Change
-1
Holders Change %
-1.33%
% of All Funds
1.65%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
25
Reduced
22
Closed
16
Calls
$2.05M
Puts
$290K
Net Calls
+$1.76M
Net Calls Change
-$2.29M

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$4.51M
2
BI
BVF Inc
California
+$4.13M
3
SI
Sofinnova Investments
California
+$970K
4
Bank of America
Bank of America
North Carolina
+$934K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$614K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$3.06M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.82M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.37M
4
O
OrbiMed
New York
-$1.23M
5
BlackRock
BlackRock
New York
-$1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Point72 Asset Management
76
Point72 Asset Management
Connecticut
– -$1.37M -170,000 Closed
BCM
77
Bridgeway Capital Management
Texas
– -$823K -101,800 Closed
BC
78
Boxer Capital
California
– -$808K -100,000 Closed
PVI
79
Pura Vida Investments
New York
– -$548K -100,000 Closed
AA
80
ALPS Advisors
Colorado
– -$334K -41,328 Closed
CAN
81
Claraphi Advisory Network
United States
– -$129K -16,000 Closed
LPL Financial
82
LPL Financial
California
– -$114K -14,130 Closed
ProShare Advisors
83
ProShare Advisors
Maryland
– -$91K -11,240 Closed
BFM
84
Boothbay Fund Management
New York
– -$81K -10,000 Closed
CSS
85
Cubist Systematic Strategies
Connecticut
– -$17K -2,144 Closed
First Manhattan
86
First Manhattan
New York
– -$12K -1,500 Closed
Royal Bank of Canada
87
Royal Bank of Canada
Ontario, Canada
– -$8K -1,026 Closed
MAM
88
Meeder Asset Management
Ohio
– -$2K -202 Closed
PNC Financial Services Group
89
PNC Financial Services Group
Pennsylvania
– -$1K -176 Closed
Daiwa Securities Group
90
Daiwa Securities Group
Japan
– -$1K -135 Closed
1 2 3
4

SNDX Hedge Fund Activity: Q4 2018 in Review

74 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2018, worth a combined $68.9M — down 44% from $124M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of SNDX and 15 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 25 added.

The largest buyer was 683 Capital Management, adding an estimated $4.51M. The largest seller was Millennium Management, cutting an estimated $3.06M.

  • 74 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2018, down from 75 in Q3 2018.
  • Funds reported $68.9M of Syndax Pharmaceuticals stock for Q4 2018, down 44% quarter-over-quarter.
  • 15 funds opened new Syndax Pharmaceuticals positions in Q4 2018 and 16 closed out, a net change of -1 holder.
  • The largest Syndax Pharmaceuticals buyer in Q4 2018 was 683 Capital Management, an estimated $4.51M added.
  • The largest Syndax Pharmaceuticals seller in Q4 2018 was Millennium Management, an estimated $3.06M sold.

Based on aggregated 13F filings for Q4 2018.